VivoSeq
Oncology

Advanced Solid Cancer

0

Pipeline Programs

1

Active Trials

8

Companies Involved

Advanced Solid Cancer is an early-stage landscape with 0 programs across 8 companies. The most active players are Samyang Biopharmaceuticals Corporation, Tianjin Hemay Pharmaceutical Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd..

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

64/100

Attrition Rate

29/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

14

clinical trials

Completed7 · 50%
Terminated4 · 29%
Unknown status2 · 14%
Active, not recruiting1 · 7%

Trial Activity

14 trials

Phase I Study of TENPA in Advanced Solid Cancer
Terminated··Phase 1·NCT02979392·19 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)